High-Dose Medroxyprogesterone Acetate for Early Breast Cancer: 13-Year Update
Author Information
Author(s): Focan C, Beauduin M, Salamon E, Greve J de, Wasch G de, Lobelle J P, Majois F, Tagnon A, Tytgat J, Belle S van, Vandervellen R, Vindevoghel A
Primary Institution: Saint-Joseph Clinics-Liège
Hypothesis
Does high-dose medroxyprogesterone acetate improve outcomes in early breast cancer patients compared to no hormonotherapy?
Conclusion
The study found that younger node-positive patients had worse outcomes with high-dose medroxyprogesterone acetate, while older patients benefited from it.
Supporting Evidence
- Younger node-positive patients had worse outcomes with high-dose medroxyprogesterone acetate.
- Older patients benefited from high-dose medroxyprogesterone acetate in terms of relapse-free survival.
- The study followed patients for a median duration of 13 years.
Takeaway
This study looked at how a certain treatment for breast cancer worked over 13 years, finding that older patients did better with the treatment, but younger patients did worse.
Methodology
A randomized trial comparing high-dose medroxyprogesterone acetate with no hormonotherapy in early breast cancer patients.
Potential Biases
Potential biases in patient selection and treatment adherence may affect the results.
Limitations
The study may not fully account for all variables affecting patient outcomes over the long term.
Participant Demographics
The study included 246 node-negative and 270 node-positive breast cancer patients, with a focus on age differences.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website